SCHEMBL211816

SCHEMBL211816

CC(C)[Si](O[C@H]1CC[C@@H](N2CC[C@@H](Cc3c(Cl)cc(-c4ccc(C(=O)N5CCN(CCF)CC5)cc4)cc3Cl)C2=O)CC1)(C(C)C)C(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 4/20 0.39
HRH3 Q9Y5N1 4/20 0.35
ALDH1A1 P00352 1/20 0.35
POLB P06746 1/20 0.35
AXL P30530 1/20 0.35
TYRO3 Q06418 1/20 0.35
MERTK Q12866 1/20 0.35
KCNA5 P22460 1/20 0.34
ABL1 P00519 3/20 0.34
BCR P11274 3/20 0.34
FASN P49327 1/20 0.34
SYK P43405 1/20 0.34
PDE5A O76074 1/20 0.33
PDE4A P27815 1/20 0.33
PDE1A P54750 1/20 0.33
PDE1B Q01064 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33
PDE7A Q13946 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL211818 1.00 MET (0.39) METHRH3ALDH1A1POLBAXL
SCHEMBL211817 1.00 MET (0.39) METHRH3ALDH1A1POLBAXL
SCHEMBL212010 1.00 MET (0.39) METHRH3ALDH1A1POLBAXL
SCHEMBL208057 0.90 HRH3 (0.42) METHRH3ALDH1A1KMT2A
SCHEMBL208056 0.90 HRH3 (0.42) METHRH3ALDH1A1KMT2A
SCHEMBL208058 0.90 HRH3 (0.42) METHRH3ALDH1A1KMT2A
SCHEMBL209786 0.89 MET (0.35) METHRH3KCNA5ABL1BCR
SCHEMBL209407 0.89 MET (0.35) METHRH3KCNA5ABL1BCR
SCHEMBL209406 0.89 MET (0.35) METHRH3KCNA5ABL1BCR
SCHEMBL209408 0.89 MET (0.35) METHRH3KCNA5ABL1BCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2016047-B1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11- BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2013-08-28 EP disclosed
US-8088776-B2 Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 ELI LILLY AND COMPANY (US) 2012-01-03 US disclosed
US-20090156571-A1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY 2009-06-18 US disclosed
EP-2016047-A1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11- BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2009-01-21 EP disclosed
WO-2007124337-A1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11- BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156571-A1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 HSD11B1, HSD17B1, HSD11B2 MET 2704/4885HRH3 1964/4885ALDH1A1 88/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.